A new study indicates that severity of amyloid deposition in the brain—not just age—may be key to determining who will benefit from new anti-amyloid therapies to delay the progression of Alzheimer’s disease.
A new study indicates that severity of amyloid deposition in the brain—not just age—may be key to determining who will benefit from new anti-amyloid therapies to delay the progression of Alzheimer’s disease.